Below are the financial statements of Immunovant, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2025 | 2024 |
|---|---|---|
| Current assets | — | — |
| Cash and cash equivalents | 713.97a | 635.37a |
| Accounts receivable | 2.08a | 5.34a |
| Prepaid expenses and other current assets | 51.18a | 24.9a |
| Income tax receivable | 0.43a | 0.17a |
| Total current assets | 767.66a | 665.77a |
| Assets | — | — |
| Operating lease right-of-use assets | 0.1a | 0.13a |
| Property and equipment, net | 0.84a | 0.46a |
| Other assets | 7.62a | 0a |
| Total assets | 776.22a | 666.37a |
| Current liabilities | — | — |
| Accounts payable | 17.66a | 7.16a |
| Accrued expenses | 50.75a | 41.3a |
| Current portion of operating lease liabilities | 0.1a | 0.14a |
| Due to Roivant Sciences Ltd. | 0.27a | 0.02a |
| Total current liabilities | 68.78a | 48.61a |
| Liabilities and stockholders’ equity | — | — |
| Total liabilities | 68.78a | 48.61a |
| Stockholders’ equity | — | — |
| Series A preferred stock | 0a | 0a |
| Preferred stock | 0a | 0a |
| Common stock | 0.02a | 0.01a |
| Additional paid-in capital | 1,945.5a | 1,441.52a |
| Accumulated other comprehensive income | 1.46a | 1.91a |
| Accumulated deficit | -1,239.52a | -825.68a |
| Total stockholders’ equity | 707.45a | 617.76a |
| Total liabilities and stockholders’ equity | 776.22a | 666.37a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Immunovant’s data sources below and access millions more through our Disclosure Search.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.